Devchand Paul
Overview
Explore the profile of Devchand Paul including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
856
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Geyer Jr C, Blum J, Yothers G, Asmar L, Flynn P, Robert N, et al.
J Clin Oncol
. 2024 Feb;
42(12):1344-1349.
PMID: 38335467
JCO The primary joint efficacy analysis of the Anthracyclines in Early Breast Cancer (ABC) trials reported in 2017 failed to demonstrate nonanthracycline adjuvant therapy was noninferior to anthracycline-based regimens in...
2.
Paul D, Vukelja S, Holmes F, Blum J, McIntyre K, Lindquist D, et al.
NPJ Breast Cancer
. 2019 Nov;
5:36.
PMID: 31667338
The non-receptor tyrosine kinase Src activation plays a role in the malignant progression of breast cancer, including development of endocrine therapy resistance and survival of bone metastases. This study investigated...
3.
Jones V, McIntyre K, Paul D, Wilks S, Ondreyco S, Sedlacek S, et al.
Oncologist
. 2019 Mar;
24(9):1153-1158.
PMID: 30833486
Background: Mammalian target of rapamycin (mTOR) inhibitor-associated stomatitis (mIAS) is a frequent adverse event (AE) associated with mTOR inhibitor therapy and can impact treatment adherence. The objectives are to evaluate...
4.
Schwartzberg B, Chin D, Dorn P, Herron D, Howell K, Kemmis T, et al.
Am J Surg
. 2018 Jul;
216(4):689-693.
PMID: 30041733
Background: American Society for Radiation Oncology (ASTRO) suitability criteria for accelerated partial breast irradiation (APBI) and the 21-gene recurrence score (RS) were evaluated for prognostic and predictive benefit in IORT...
5.
Blum J, Flynn P, Yothers G, Asmar L, Geyer Jr C, Jacobs S, et al.
J Clin Oncol
. 2017 Apr;
35(23):2647-2655.
PMID: 28398846
Purpose Docetaxel and cyclophosphamide (TC) was superior to doxorubicin and cyclophosphamide (AC) in a trial in early breast cancer. However, activity of TC relative to AC regimens with a taxane...
6.
Yardley D, Reeves J, Dees E, Osborne C, Paul D, Ademuyiwa F, et al.
Clin Breast Cancer
. 2016 Aug;
16(6):471-479.e1.
PMID: 27569274
Background: Use of antiangiogenic agents in treatment of metastatic breast cancer (MBC) remains controversial. We evaluated the efficacy and safety of ramucirumab and eribulin versus eribulin alone as third- to...
7.
Thompson H, Sedlacek S, Wolfe P, Paul D, Lakoski S, Playdon M, et al.
Nutrients
. 2015 Jul;
7(7):5156-76.
PMID: 26132992
Women who are obese at the time of breast cancer diagnosis have higher overall mortality than normal weight women and some evidence implicates adiponectin and leptin as contributing to prognostic...
8.
OShaughnessy J, Koeppen H, Xiao Y, Lackner M, Paul D, Stokoe C, et al.
Clin Cancer Res
. 2015 Jun;
21(19):4305-11.
PMID: 26041745
Purpose: We conducted a randomized phase III study to determine whether patients with early breast cancer would benefit from the addition of capecitabine (X) to a standard regimen of doxorubicin...
9.
Thompson H, Sedlacek S, Playdon M, Wolfe P, McGinley J, Paul D, et al.
PLoS One
. 2015 May;
10(5):e0127366.
PMID: 26010254
Unlabelled: Body weight management is not emphasized in clinical practice guidelines for breast cancer survivors, reflecting the lack of evidence that weight loss improves prognosis. Even if this situation changes,...
10.
Frazier T, Fox K, Smith J, Laronga C, McSwain A, Paul D, et al.
Pharmaceuticals (Basel)
. 2015 Mar;
8(1):107-22.
PMID: 25789420
To assess clinical utility of the 21-gene assay (Oncotype DX® Recurrence Score®), we determined whether women with HER2(-)/ER+ pN1mi breast cancer with low (<18) Recurrence Scores results are given adjuvant...